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ABSTRACT
The Allele Frequency Net Database (AFND, www.
allelefrequencies.net) provides the scientific commu-
nity with a freely available repository for the stor-
age of frequency data (alleles, genes, haplotypes
and genotypes) related to human leukocyte anti-
gens (HLA), killer-cell immunoglobulin-like receptors
(KIR), major histocompatibility complex Class I chain
related genes (MIC) and a number of cytokine gene
polymorphisms in worldwide populations. In the last
five years, AFND has become more popular in terms
of clinical and scientific usage, with a recent in-
crease in genotyping data as a necessary compo-
nent of Short Population Report article submissions
to another scientific journal. In addition, we have de-
veloped a user-friendly desktop application for HLA
and KIR genotype/population data submissions. We
have also focused on classification of existing and
new data into ‘gold–silver–bronze’ criteria, allowing
users to filter and query depending on their needs.
Moreover, we have also continued to expand other
features, for example focussed on HLA associations
with adverse drug reactions. At present, AFND con-
tains >1600 populations from >10 million healthy in-
dividuals, making AFND a valuable resource for the
analysis of some of the most polymorphic regions in
the human genome.
INTRODUCTION
TheAllele FrequencyNetDatabase (AFND)was originally
designed to provide a freely available resource for the stor-
age of frequency data on the polymorphisms of several im-
mune related genes, including the human leukocyte anti-
gens (HLA) system, killer-cell immunoglobulin-like recep-
tors (KIR), major histocompatibility complex class I chain-
related genes (MIC), and a number of cytokine gene poly-
morphisms (1). These loci, which are known to be among
the most polymorphic regions in humans, play important
roles in the immune system response. Different research ar-
eas have investigated these genomic regions due to their im-
portance in donor-recipient matching in solid organ and
stem cell transplantation outcome (2,3), response to vari-
ous infectious diseases or susceptibility to the development
of autoimmune diseases (4,5).
In the last decade, there has been a substantial increase
in research demonstrating that individuals carrying partic-
ular HLA alleles have a greater or lesser risk of developing
immune-mediated adverse responses to particular drugs. As
such, there has been growing interest in the field of phar-
macogenetics research and clinical practice to understand
global distributions of HLA alleles for profiling risk (6,7),
which can be assisted by healthy populations in AFND.
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In the last five years, we have also started to capture case
and control frequencies (and further statistics) from studies,
to help understand HLA-adverse drug reactions (8). HLA
population data, sourced fromAFND also often underpins
anthropology studies (9–11), as well as in silico analyses for
vaccine development based on epitope prediction (12–14),
among many other applications.
There are currently >23 000 alleles that have been re-
ported at the IMGT/HLA database (Release 3.37.0, July
2019) for HLA, and nearly 1000 alleles in the IPD-KIR
database (Release 2.8.0, November 2018) for KIR (15,16).
The vast majority of frequency records available in AFND
(∼90%) corresponds to eight routinely-typed loci HLA-A,
-B, -C, -DRB1, -DQB1, -DPA1 and -DPB1, although not
all populations have been typed for all these loci. Moreover,
there has been a recent increase in the number of popula-
tions genotyped for KIR and their corresponding HLA-
ligands, which are also broadly analysed in disease associa-
tion studies and transplantation.
The first release of AFND in 2003 consisted of only a
few sections and frequencies of HLA alleles/allelic lineages.
However, in the last 17 years, many more tools have been
incorporated into the database, producing a new release in
2011 and an update in 2015, both published inNucleic Acid
Research database issues (17,18). Over the past three years,
nearly 100 000 different users from 186 countries have ac-
cessed the database. In this article, we describe an update of
the available data sets, new developments for data submis-
sion and data sharing, as well as introducing a ‘gold–silver–
bronze’ (GSB) criteria on data quality.
DESCRIPTION OF AFND AND SOURCES OF DATA
Database content
TheAFNDwebsite collects data from fourmain sources: (i)
data from peer-reviewed publications, (ii) data from pop-
ulations that are analysed at International HLA and Im-
munogenetics Workshops (IHWSs), (iii) submissions from
individual laboratories across the world, and,more recently,
(iv) short publication reports (SPR) in collaboration with
theHuman Immunology journal (19,20), as shown in Figure
1A. As of September 2019, we have compiled information
on >1600 healthy populations from >10 million people.
The HLA section contains the majority of the submissions
with 1228 populations, followed by KIR 256, MIC 64 and
124 populations analysed for cytokine gene polymorphisms
(Table 1). Currently, population data sets from 141 coun-
tries are included within AFND, with the highest coverage
in Europe (396 populations), followed by North America
(256 populations), South Asia (249 populations) and South
and Central America (232 populations). In this database,
users are able to browse for allele, gene, genotype or hap-
lotype frequencies for HLA, KIR, MIC and cytokines, de-
pending on their availability.
Other databases
AFND is currently hosting other resources, beyond data on
healthy individuals. The database for HLA adverse drug re-
actions (HLA-ADR, http://allelefrequencies.net/hla-adr/)
comprises nearly 2000 records from more than 100 studies,
covering 46 drugs/drug-classes mainly compiled from liter-
ature searches. HLA-ADR allows users to query by drug,
disease, locus, allele and so on, returning all the recorded
data from case-control studies, including P-values for sig-
nificant (and in some cases non-significant) associations.
In addition, the KIR and Disease Database (KDDB, http:
//allelefrequencies.net/diseases/) captures results from dis-
ease association studies in KIR with ∼1500 records from
more than 270 studies, including auto-immune disorders,
infectious disease, cancer and pregnancy-related complica-
tions for which studies have demonstrated that the profile
of KIR alleles, genes or haplotypes carried by an individual
can affect risk. HLA-ADRandKDDBdatabases have been
thoroughly described in two previous publications (8,21).
Both HLA-ADR and KDDB can be queried and filtered in
various ways, enabling users to assemble data sets for meta-
analyses amongst other uses.
Tools and searching mechanisms
AFND contains a set of different systems to analyse data,
as well as searching mechanisms for browsing frequency
and genotype raw data. A list of the different tools is
shown in Table 2. Despite the number of tools provided
in AFND, according to our statistics, healthy population-
related searches are among the most popular surveys in
AFND with ‘HLA allele frequency search’ covering 27%
of the hits in the website, followed by ‘HLA haplotype fre-
quency search’ with 22% from a total of 221k visits over the
last three years.
Data quality, submissions and data sharing
Although all submissions by contributors are considered
for inclusion, AFND introduces minimal criteria for HLA
and KIR populations before they become publicly acces-
sible on the website (Figure 1B). These minimum require-
ments include validation of allele names, which comply
with the IMGT/HLA and IPD-KIR official nomenclature
guidelines, homogenization on the naming of the popula-
tions, an appropriate assignment of the geographical re-
gion to which the population belongs and validation of fre-
quency data using the AFND Upload Tool for SPR sub-
missions. A full list of requirements can be consulted at
http://allelefrequencies.net/quality.asp.
Since 2015, AFNDhas also started receiving submissions
for SPR in which the majority of the data corresponds to
two-field (or greater) according to the IMGT/HLAnomen-
clature (Table 3). For this new section users are able to
download the submitted data in CSV files. In addition, KIR
genotype raw data can be downloaded as CSV files.
Gold, silver and bronze (GSB) standard HLA data sets
In order to allow users to browse data sets according to their
needs, HLA populations were classified into three groups
based on the sample size, level of resolution and frequen-
cies: gold, silver and bronze standards. Three important cri-
teria (allele frequency sums to 1 [±1.5%], sample size >50,
two-field resolution) define the ‘Gold Standard’ data set. A
‘Silver Standard’ data set is determined via less stringent cri-
teria with regards sample size (i.e. any sample size) and any
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Table 1. Frequency data sets by polymorphic region at AFND, figures as of September 2019
Polymorphic region Population studies Gene/allele data Haplotype data Genotype data
HLA 1228 1213 596 157
KIR 256 255 - 171
Cytokine 124 124 - -
MIC 62 62 23 -
Total 1672 1656 619 171
Table 2. Overview of the most popular searches and tools available at AFND
Polymorphic region Tool Description
HLA Classical and non-classical allele frequency
search
Querying tool to explore allele and phenotype frequencies
in one or many populations from the given criteria.
Haplotype frequency search Tool to consult a particular haplotype in a set of
populations at two or more loci.
Rare HLA alleles search Section to ascertain the rarity of HLA alleles based on the
confirmation from different databases and individual
laboratories.
Amino acid frequencies in populations Interactive tool to examine frequencies in a given
population comparing alleles differing at amino acid
positions.
Lower resolution search+ Tool to search for low resolution data from a given high
resolution allele.
Allele survey+ This tool provides a summary of statistical information
regarding that allele, based on our Gold Standard
populations, which are organized by geographical regions.
Genotype data browser+ Searching mechanism to explore genotype raw data
submitted via the short population reports.
KIR Allele frequency search Querying tool to explore allele and phenotype frequencies
in one or many populations from the given criteria.
Genotype frequency search Tool which allows users to display genotype frequencies of
a given profile.
Cell-lines and CEPH families Section that provides a reference of KIR cell-lines and
Centre d’ Etude du Polymorphisme Humain (CEPH)
families typed at allele level.
Linkage disequilibrium (LD) analysis+ Tool for the analysis of LD among KIR genes by
population, country, geographical region and ethnicity.
Cytokines Cytokine frequency search Querying tool to explore allele frequencies in one or many
populations from the given criteria.
MIC Allele frequency search Querying tool to explore allele and phenotype frequencies
in one or many populations from the given criteria.
MIC-HLA association frequency search Section that provides frequencies of MIC and HLA
associations.
Online submissions Populations Online submission tool for a new population.
Confirmation of rare alleles Section for the confirmation of rare HLA alleles.
+New tools and searches since 2015.
Table 3. Genotype submissions data to AFND by geographical region and level of resolution
Geographical region Countries Individuals ≥ Two-field resolution (%) Different allelesa
South and Central America 8 34 334 46 362
Europe 11 32 856 96 458
South-East Asia 4 14 790 100 187
North-East Asia 1 3568 97 70
South Asia 2 3392 100 212
North America 1 496 100 75
Sub-Saharan Africa 2 359 100 114
Oceania 1 199 100 26
Western Asia 1 52 100 43
Total 31 90 046
aNumber of different alleles at two-field resolution.
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Figure 1. Overview of the main features in AFND. (A) Data sets are sourced from short population reports or direct AFND user submissions, both using
the upload tool, from International HLA and Immunogenetics Workshops and from other peer reviewed publications, with allele and gene nomenclature
synchronized with IMGT/HLA; (B) data undergo curation, including classification into gold–silver–bronze quality, and are stored under the different
sections of the database; (C) a variety of query and custom-built visualization tools allow users to explore the different data sets.
level of resolution (but population frequency still sums to
1), for example included to allow users to consult data from
a particular geographical region or country if this is not
covered by the gold standard data. Finally, ‘Bronze Stan-
dard’ includes populations that do not meet these criteria,
but remain in AFND as a record of published data sets
which are likely to require some care when interpreting. The
Bronze Standard set includes all data at one-field resolution
for which very large sets exist, for example from Bone Mar-
row Donor Registries. Following these criteria, AFND has
organized all datasets into these categories, resulting in cov-
erage of many countries by several Gold Standard popula-
tions, as shown in Figure 2. Figure 2 does however demon-
strate that some regions of Africa and Central Asia still do
not have any data coverage, and thus we would especially
encourage submissions from these countries.
FUTURE DEVELOPMENTS
We are currently expanding the offering in AFND to add
tools to assist in clinical transplantation settings. In theUK,
393 (8%) of adult patients on the kidney transplant waiting
list have waited over 5 years for an offer and over 80% are
classified as ‘highly sensitized patients’ with HLA-specific
antibodies directed towards at least 85% of donors. Such
patients also suffer increased morbidity and mortality com-
pared to less sensitized patients. Antibodies are often as-
signed using single antigen bead (SAB) assays but there re-
mains much debate as to the clinical significance of anti-
bodies detected solely by this method and the clinical signif-
icance of the quantitative threshold used to determine the
presence of a given antibody. We will shortly be releasing
the AbDelister tool, which allows users to filter a patient’s
longitudinal SAB-definedHLA-specific antibodies, altering
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Figure 2. Map showing the distribution of countries with data available for at least one classical HLA locus. Countries with no frequency/genotype data
are shown in white; countries with only silver and/or bronze standard populations are shown in grey; gold standard populations are shown in light yellow
(1–4 populations with gold standards), yellow (6–9), dark yellow (10–19), brown (≥20).
the quantitative threshold used and time intervals into lev-
els. Up to five filter levels can be set for each locus and anti-
bodies within each can be removed from a patient’s profile
to test the potential for increasing the percentage of donors
from which the patient could receive a kidney. We welcome
feedback and testing of the AbDelister tool.
AFND will continue to develop over the coming years
via the addition of more data, and providing new querying
mechanisms, for example in response to user requests. We
also wish to provide capabilities for performing statistical
analyses online as well as incorporation of other applica-
tions for data visualization, for example allowing popula-
tions to be clustered. In addition, we are currently includ-
ing support for nomenclature that describes ambiguity in
the typing (such as ‘G’ and ‘P’ codes) for HLA alleles, via
the AFND Upload tool. Finally, we are also moving into a
new website version which will include a set of tutorials and
documentation of the data sets and tools available.
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